CanSino Biologics Inc (CASBF)
2.10
0.00 (0.00%)
USD |
OTCM |
May 16, 16:00
CanSino Biologics Total Liabilities (Quarterly): 486.51M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 486.51M |
| December 31, 2023 | 568.71M |
| September 30, 2023 | 522.52M |
| June 30, 2023 | 541.51M |
| June 30, 2023 | 541.51M |
| December 31, 2022 | 612.14M |
| June 30, 2022 | 556.90M |
| June 30, 2022 | 556.90M |
| December 31, 2021 | 521.85M |
| Date | Value |
|---|---|
| June 30, 2021 | 500.40M |
| June 30, 2021 | 500.40M |
| December 31, 2020 | 103.66M |
| June 30, 2020 | 47.04M |
| June 30, 2020 | 47.04M |
| December 31, 2019 | 44.87M |
| June 30, 2019 | 41.97M |
| June 30, 2019 | 41.97M |
| December 31, 2018 | 42.67M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
41.97M
Minimum
Jun 2019
612.14M
Maximum
Dec 2022
366.82M
Average
500.40M
Median
Jun 2021
Total Liabilities (Quarterly) Benchmarks
| Sinovac Biotech Ltd | 1.635B |
| CASI Pharmaceuticals Inc | 51.10M |
| Zai Lab Ltd | 226.27M |
| Gracell Biotechnologies Inc (DELISTED) | 36.85M |
| Adagene Inc | 45.17M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.204B |
| Shareholders Equity (Quarterly) | 717.58M |
| Debt to Equity Ratio | 0.412 |
| Current Ratio | 2.389 |
| Net Debt Paydown Yield | 2.61% |